BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
2 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, Lee SH, Seo GS, Park SJ, Choi CH, Jung SA, Hong SN, Im JP, Kim ES; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8:384-91. [PMID: 24144611 DOI: 10.1016/j.crohns.2013.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]